Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
Journal of Clinical Oncology（2022）
关键词
metastatic breast cancer,breast cancer,trastuzumab deruxtecan,trastuzumab emtansine,t-dxd,destiny-breast
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要